Navigation Links
Cerulean Completes Enrollment of Randomized Phase 2 Study of CRLX101 in Non-Small Cell Lung Cancer
Date:7/2/2012

CAMBRIDGE, Mass., July 2, 2012 /PRNewswire/ -- Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC).  The company also announced that it has dosed the first patient in a second tumor type.

(Logo: http://photos.prnewswire.com/prnh/20120702/NE33542LOGO )

"Completing enrollment of our Phase 2 study is a significant company milestone and speaks to our team's ability to execute on the CRLX101 development program," said Oliver Fetzer, Ph.D., president and chief executive officer of Cerulean.  "CRLX101 is being evaluated to determine whether it can address the current treatment gap in NSCLC patients who are not likely to benefit from the approved molecularly targeted drugs.  We believe that the biological activity observed in our Phase 1 and Phase 2a studies is encouraging and supports the continued development of CRLX101 to evaluate whether it translates into clinical benefit for patients."

The fully-enrolled 150-patient randomized Phase 2 study is designed to assess the efficacy and safety of CRLX101 as a monotherapy for advanced NSCLC following one or two prior regimens of therapy.  The primary endpoint of the study is overall survival, and the patients will additionally be assessed for progression-free survival, tumor response, and pharmacokinetic parameters.  Final data from the study is expected by late 2012.

"The design of this trial has been well received and I am pleased to see that we were able to complete enrollment so quickly," said John Ryan, Ph.D., M.D., chair of the Medical Advisory Board of Cerulean.  "I al
'/>"/>

SOURCE Cerulean Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
2. InnoPharma Completes $15 Million Series A Financing
3. Aratana Therapeutics Completes $15 Million Series B Financing
4. CeNeRx BioPharma Completes $4.85 Million Financing
5. PDL BioPharma Completes Regular Quarterly Dividend Payment
6. MiMedx Group Completes $5,000,000 Private Placement
7. goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit
8. Auxogyn Completes $20 Million In Series A Funding
9. CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
10. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
11. Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Smarter Alloys ... a revolutionary new archwire that allows orthodontists to simultaneously apply different forces to ... efficacy of SmartArch. “We’re thrilled about taking SmartArch one step closer to commercial ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... around 19% during the forecast period (2015 to 2020). The market is mainly ... government and corporate funding for R&D. However, lack of adequate healthcare and research ...
(Date:6/29/2015)... According to a new market research report "Aptamers Market ... by Technology (SELEX, Other Technologies), by End Users (Academic Research ... 2020", published by MarketsandMarkets, the global Aptamers Market is expected ... 2015, at a CAGR of 17.89%. Browse ... igures spread through 125 P ages ...
(Date:6/26/2015)... June 26, 2015  SeraCare Life Sciences, a ... today announced that it has signed a Cooperative ... Cancer Institute (NCI), part of the National Institutes ... controls for cancer assays.  The CRADA will investigate ... quantitate control DNA biosynthetics spiked into a genomic ...
Breaking Biology Technology:New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3
... Therapeutics Corporation (Nasdaq: UTHR ) announced today ... annual financial results before market open on Tuesday, February ... Tuesday, February 17, 2009, at 9:00 a.m. Eastern Time. ... international callers dialing 719-325-4753. A rebroadcast of the ...
... or Phase 0 clinical testing has been gaining ... the drug development process in the years to ... preclinical testing and technology dependence is also expected ... growth opportunities in this sector.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )"There ...
... BASEL, Switzerland, Feb. 10 Syngenta today announced that ... Rice Research Institute (ARRI) of Anhui Academy of Agricultural ... conducting laboratory and field tests of novel gene functions ... optimization in key crops such as corn and soybean. ...
Cached Biology Technology:Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 2Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 3Syngenta Enters Into Research Collaboration With Anhui Academy, China 2Syngenta Enters Into Research Collaboration With Anhui Academy, China 3
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
(Date:6/23/2015)... GARDENS, Fla. , June 23, 2015 ... identity management and authentication solutions, today announced enhanced ... strong, multi-factor authentication solution.  The enhancements build ... use of the DigitalPersona Altus platform and ... reader compatibility. In today,s environment ...
(Date:6/17/2015)... Germany , June 17, 2015 ... today launched new Investigator ® STR assay kits for ... the United States . The new genetic fingerprint kits ... markers (short tandem repeats or STRs) for DNA matching. They ... quality of DNA in each sample, a novel QIAGEN technology ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... plants are all around us and are phenomenally successfulbut how ... they come from? This question bothered Darwin and others ... Botanical Journal of the Linnean Society indicates that ... Sherwin Carlquist, a research botanist at the Santa Barbara Botanic ...
... is developing into one of the nation,s premiere tools in ... reservoirs, such as depleted oil and natural gas reservoirs, can ... a major greenhouse gas. CO2 would be captured at coal ... CO2, and transported by pipeline to reservoirs where it would ...
... million grant to North Carolina State University will allow ... how genes impact the type and amount of "glue," ... of lignin, which binds fibers together to form wood, ... biofuels and construction materials. The National Science Foundation ...
Cached Biology News:Department of Energy supports carbon sequestration research, University of Miami receives $1.7 million 2NC State receives NSF grant to discover plant 'switchboards' 2NC State receives NSF grant to discover plant 'switchboards' 3
Request Info...
Sprague Dawley rats, 7-8 weeks of age, mixed gender; collected by exsanguination in Alsever's solution at 1:2 dilution...
2-min, single-step add-mix-measure assay for luciferase expression and HTS in mammalian cells. Linear detection range: 2 fg to 46 ng luciferase....
... Error-free cloning of BAC (100+kb), fosmid (40kb), ... insert stability than any othe BAC vector. ... high yields and easy recombinant DNA purification. ... transcription-free (pSMART VC) vectors for the highest ...
Biology Products: